Genmab — November 2015
-
Ofatumumab er vel nu kun interessant indenfor MS. Novartis starter formodentlig fase III i første halvår 2016.
-
Hvis det lykkes kan der være milliard potentiale her
-
Jan på børsen igen-igen. Dara vil sælge minimum usd 5mia - http://borsen.dk/nyheder/virksomheder/artikel/1/315316/genmab-topchef_darzalex_kan_saelge_for_over_5_mia_dollar.html
-
og nu er han igang med at tale non-MM indikationer op. "Potential do really-really well" - "Janssen never seen better pre-clinical data" osv osv
-
nu mangler vi bare, at der kommer lidt opmærksomhed omkring det faktum, at duobody er røget i klinikken. Det er virkelig en stor begivenhed i min bog!
-
Sikkert rigtigt med Ofa og MS, selv om det svært at forstå, at det ikke interesserer nogen med Ofa i first line CLL når man ser data som: Overall response rate (ORR) was 98% (46/47) with 47% (22/47) CR. https://ash.confex.com/ash/2015/webprogram/Paper81421.html
-
nu er det jo ikke enten eller - ofa skal nok bidrage i cancer, men det bliver nok ikke, hvad stoffet egentlig havde potentiale til oprindeligt
-
-
Solsen...Dyrk lige dettte link.
-
-
Også for alle andre
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind